Project Grant R43DK142320

Award Date 8/1/25
Completion Date 7/31/26
Dollars Obligated $311K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $298,364 in funding to Immunoshield Therapeutics Inc. to investigate optimal islet density and dosage within macroencapsulation devices for clinical islet transplantation to treat type 1 diabetes. The research aims to address limitations in current macroencapsulation approaches, such as...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
This Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $275,000 in funding to Islex Therapeutics, LLC to develop antibody therapeutics for the treatment of stage 3 type-1 diabetes (T1D). The project aims to harness the synergistic effects of autoimmune protection, insulin supplementation, and targeted delivery of mitogenic drugs to the pancreatic islet, the disease site of T1D. The research...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This Project Grant award of $500,928 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of an early detection test for Type 1 Diabetes (T1D) by Pupil Bio, Inc. The project aims to leverage next-generation sequencing (NGS) for methylation analysis (methyl-seq) of cell-free DNA (cfDNA) to identify B cell-specific methylation patterns that can serve as...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $235,403 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Johns Hopkins University. The funding will support the development of a membrane-reconstituted ZNT8 biosensor to detect cell-surface ZNT8 autoantibodies in the peripheral blood of patients with type-1 diabetes. This novel bioanalytical tool aims to enable the early detection of islet...
This federal Project Grant award, R01DK140781, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $1,449,016 award aims to use advanced immunoproteomics technologies to comprehensively screen for microbial infections associated with increased or decreased risk of islet autoimmunity and type 1 diabetes in children participating in the TEDDY study. The project...

This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic efficacy in reversing new-onset T1D in mice, and ability to protect human islets against T-cell cytotoxicity. This Phase I SBIR project lays the groundwork for future Phase II development focused on preclinical toxicology studies and manufacturing, ultimately leading to clinical trials in patients with Stage 2 and new-onset Stage 3 T1D.

Generated 8/5/25, 6:19 AM